Liquidia Co. (NASDAQ:LQDA) CEO Sells $263,200.54 in Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares in the company, valued at $12,005,905.06. This trade represents a 2.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Liquidia Stock Performance

Shares of LQDA opened at $11.36 on Wednesday. The stock has a 50-day simple moving average of $11.20 and a 200-day simple moving average of $11.01. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.99. The stock has a market capitalization of $961.48 million, a PE ratio of -6.97 and a beta of 0.23.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LQDA. Whitefort Capital Management LP raised its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after buying an additional 210,753 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Liquidia by 18.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after buying an additional 32,076 shares during the last quarter. Finally, HighVista Strategies LLC boosted its position in shares of Liquidia by 48.6% during the 3rd quarter. HighVista Strategies LLC now owns 180,947 shares of the company’s stock worth $1,809,000 after acquiring an additional 59,193 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th. Finally, Lifesci Capital initiated coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).